62 results on '"Ayello, Janet"'
Search Results
2. Adenoviral Cellular Therapy with Adenovirus (ADV)-Specific Cytotoxic T-Lymphocytes (CTLs) for Resistant Infections in Children, Adolescent, and Young Adult (CAYA) Patients Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT): A Promising Approach
3. Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)
4. Immune Profiling Following TCR Alpha Beta T and B-Cell Depleted Hematopoietic Cell Transplantation in Pediatric Patients
5. Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-γ Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)
6. Anti-IL1RAP Chimeric Antigen Receptor Modified Ex-Vivo Expanded TGF-Beta Imprinted Natural Killer Cells Against Ewing Sarcoma
7. Manufacture, Immunological Characterization and Clinical Response of GMP Grade Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System
8. Targeting Ewing Sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti-Mcam Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells
9. Feasibility, Safety and Efficacy of Haploidentical Viral Cytotoxic T-Lymphocytes for Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID) Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT)
10. Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)
11. Safety and Efficacy of High Dose Granulocyte Colony Stimulating Factor Mobilization in Familial Haploidentical Adult Donors with Sickle Cell Trait Followed By CD34+ Cell Enrichment and Mononuclear Cell Add-Back Prior to Haploidentical Allogeneic Transplantation in High-Risk Sickle Cell Disease Recipients
12. Optimization of Gating of IFN-Gamma Positive Viral Specific Cytotoxic T-Cells (vCTLs) Following Viral Peptivators® Stimulation Utilizing the Cytokine Capture System on the Clinimacs® Prodigy: Quality Control of the Viral CTL Consortium (VIRCTL)
13. Safety and Efficacy of GMP Clinical Grade Manufacturing of Virus Specific Cytotoxic T Lymphocytes (vCTLS) Against Cytomegalovirus (CMV), Epstein Barr Virus ( EBV), Adenovirus (ADV) and BKV to Treat Medically Refractory Viral Infections Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Children, Adolescents and Young Adults (CAYA) (IND# 17449)
14. Stable to Improved Long Term Cardiac and Pulmonary Function in Children, Adolescents, and Young Adults with High Risk Sickle Cell Disease Following Myeloimmunoablative Conditioning and Familial Haploidentical Stem Cell Transplantation
15. Enrichment of CD34+ Hematopoietic Progenitor STEM CELLS and Depletion of CD3 CELLS Utilizing the Clinimacs®: Comparison of Immediate Versus Next Day Processing
16. The Safety and Efficacy of Targeted Virus Specific Cytotoxic T-Lymphocytes (VST) Manufactured By the IFN-g Cytokine Capture System (CCS) for the Treatment of Refractory Adenovirus (ADV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) and BK Virus (BKV) in Children, Adolescents and Young Adults (CAYA) after Allogenic Hematopoietic Stem Cell Transplantation (Allo-HSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID) (IND# 17449)
17. Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)
18. Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) with Human Placenta-Derived Stem Cells (HPDSC) Combined with Unrelated Cord Blood (UCB) for Malignant and Non-Malignant Disorders (IND 14949)
19. Sustained Donor Chimerism and Rapid Immune Cell Reconstitution with a Low Probability of Gvhd Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)
20. Rapid Manufacture and Isolation of Highly Viable Interferon-γ Expressing Virus-Specific T Cells: Validation Results for the Virus-Specific Cytotoxic T-Lymphocyte Consortium for Refractory EBV, CMV, and Adenovirus Infections
21. Hematopoietic Stem Cell Transplantation with Human Placenta-Derived Stem Cells Combined with Unrelated Cord Blood for Malignant and Non-Malignant Disorders (IND 14949)
22. Safety and Efficacy of Myeloablative Conditioning Autologous Stem Cell Transplantation, Targeted Immunotherapy, and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Children, Adolescents, and Young Adults with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
23. Combining ROR1- Specific Chimeric Antigen Receptor (CAR) NK Cells with IL-15 Superagonist (N-803/ALT-803) to Target Chemotherapy Resistant Neuroblastoma
24. Processing of G-CSF Mobilized Peripheral Blood Hematopoietic Progenitor Cells (PB-HPC) from Matched- Related or Unrelated Donors Undergoing CD34 Enrichment with T Cell Addback in Children, Adolescents and Adults with Malignant and Nonmalignant Diseases: Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism
25. Assessment of Safety and Efficacy of PBSC Mobilization with G-CSF and CD34+ Enrichment and Pbmnc (CD3+) Addback in Familial Haploidentical (FHI) Adult Donors with Sickle Cell Disease Trait (SCDT) Prior to Allogeneic HSCT of High-Risk SCD Patients
26. Immune Reconstitution in Children and Adolescents with High Risk Sickle Cell Disease (SCD) after Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback (Ind 14359)
27. Assessment of Safety and Efficacy of PBSC Mobilization with G-CSF and CD34+ Enrichment and Pbmnc (CD3+) Addback in Familial Haploidentical (FHI) Adult Donors with Sickle Cell Disease Trait (SCDT) Prior to Allogeneic HSCT of High-Risk SCD Patients
28. Comparison of T & NK Cell Donor Chimerism & Hematopoietic Engraftment Following Allogeneic Hematopoetic Stem Cell Transplantation in Pediatric Recipients Receiving Bone Marrow (BM) or Umbilical Cord Blood and/or Human Placental Derived Stem Cells (HPDSC)
29. Safety & Efficacy of Liposomal Amphotericin B Followed By Micafungin to Prevent Invasive Fungal Infection in Pediatric Allogeneic Stem Cell Transplantation Recipients
30. A Pilot Trial of Unrelated Donor Human Placenta-Derived Stem Cells (HPDSC) in Conjunction with Single Unrelated Cord Blood Transplantation (UCBT) in Children with Malignant and Non-Malignant Disease (IND 14949)
31. Significant Suppressive Effects of Human Umbilical Cord Blood (CB) Derived Unrestricted Somatic Stem Cells (USSCs) on Human T-Cell Function and in a Human (Hu) NSG Acute Graft Versus Host Disease (aGVHD) Model
32. Neurocognitive & Neurological Outcomes in Children, Adolescents & Young Adults with High-Risk SCD Who Have Undergone Familial Haploidentical (FHI) Allosct Utilizing CD34 Enrichment and T Cell Addback Following Myeloimmunoablative Conditioning (MAC)
33. ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas
34. Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)
35. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy
36. Regulation of cytokine release and anti-tumor effect of anti-CD20 CAR modified expanded natural killer cells by ALT-803, an IL-15 superagonist
37. Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer Cells Against Burkitt Lymphoma (BL)
38. Collection and Processing Outcomes of G-CSF Mobilized Peripheral Blood Stem Cells (PBSC) Collected from Parental Haploidentical Stem Cell Sickle Cell Trait Donors of Patients Undergoing CD34 Enriched Transplantation for High-Risk Sickle Cell Disease (IND
39. Enhanced in-Vitro and in-Vivo Targeting of Rituximab Sensitive and Resistant Burkitt Lymphoma (BL) By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells in Combination with a Histone Deacetylase Inhibitor, Romidepsin
40. A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)
41. Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation Utilizing CD34 Enrichment and T Cell Addback in Children, Adolescents & Adults with High-Risk Sickle Cell Disease. Rapid Engraftment, Low Incidence of Agvhd, and Sustained Donor Chimerism
42. Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation in Patients with High Risk Sickle Cell Disease (SCD)
43. Ex-Vivo Expansion of Previously Cryopreserved, Thawed and Re-Cryopreserved Cord Blood Mononuclear Cells (CBMC) Utilizing K562-mbIL21-41BBL; Potential for Adoptive Cellular Immunotherapy Post Umbilical Cord Blood Transplantation (UCBT)
44. A pilot trial of unmatched human placental derived stem cells (HPDSC) infusion in conjunction with unrelated cord blood transplantation (UCBT) in children and young adults with malignant and non-malignant diseases
45. ROR1 expressing neuroblastoma (NB), medulloblastoma (MB), and ewing’s sarcoma (ES) can be effectively targeted with nk cells modified to express an anti ROR1 chimeric antigen receptor (CAR)
46. Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait Prior to Haploidentical Stem Cell Transplantation in Their Children with High-Risk Sickle Cell Disease
47. Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in Vitro and In Humanized NSG Mice
48. A Pilot Trial of Unrelated Cord Blood Transplantation (UCBT) and Unmatched Human Placental Derived Stem Cells (HPDSC) in Children and Young Adults with Malignant and Non-Malignant Disease
49. Neuroblastoma and Ewing's Sarcoma Associated with ROR1 Expression Can Be Effectively Targeted with NK Cells Modified to Express an Anti ROR1 Chimeric Antigen Receptor
50. Treatment of High-Risk Sickle Cell Disease (SCD) with Familial Haploidentical (FHI) T-Cell Depleted (TCD) Stem Cell Transplantation with T-Cell Addback (IND 14359)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.